[go: up one dir, main page]

PT2061561E - Composições para tratar o cancro - Google Patents

Composições para tratar o cancro

Info

Publication number
PT2061561E
PT2061561E PT78373263T PT07837326T PT2061561E PT 2061561 E PT2061561 E PT 2061561E PT 78373263 T PT78373263 T PT 78373263T PT 07837326 T PT07837326 T PT 07837326T PT 2061561 E PT2061561 E PT 2061561E
Authority
PT
Portugal
Prior art keywords
compositions
treating cancer
cancer
hydroxylase
steroid
Prior art date
Application number
PT78373263T
Other languages
English (en)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2061561(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of PT2061561E publication Critical patent/PT2061561E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
PT78373263T 2006-08-25 2007-08-23 Composições para tratar o cancro PT2061561E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
PT2061561E true PT2061561E (pt) 2013-10-09

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
PT78373263T PT2061561E (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro
PT121605869T PT2478907T (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT121605869T PT2478907T (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro

Country Status (20)

Country Link
EP (3) EP2478907B1 (pt)
JP (10) JP2010501575A (pt)
KR (4) KR20200125776A (pt)
CN (2) CN104306977A (pt)
AU (6) AU2007287098C1 (pt)
CA (1) CA2661422C (pt)
CY (2) CY1115477T1 (pt)
DK (2) DK2478907T3 (pt)
ES (2) ES2428634T3 (pt)
HR (2) HRP20130961T1 (pt)
HU (1) HUE054495T2 (pt)
IL (3) IL197211A0 (pt)
LT (1) LT2478907T (pt)
NO (2) NO20091190L (pt)
NZ (1) NZ597830A (pt)
PL (2) PL2478907T3 (pt)
PT (2) PT2061561E (pt)
RS (2) RS52956B (pt)
SI (2) SI2061561T1 (pt)
WO (1) WO2008024484A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597830A (en) 2006-08-25 2013-02-22 Cougar Biotechnology Inc Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CA2703780A1 (en) * 2007-10-29 2009-05-07 Takeda Pharmaceutical Company Limited Drug for prophylaxis or treatment of cancer
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
SG10201504303SA (en) 2011-04-01 2015-07-30 Genentech Inc Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
BR112014030099A2 (pt) * 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR20160023641A (ko) * 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3824908A1 (en) * 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CA3131034A1 (en) 2019-03-06 2020-09-10 Matthew J. Sharp Abiraterone prodrugs
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
MX2022013043A (es) * 2020-04-16 2023-01-24 Tavanta Therapeutics Hungary Incorporated Metodos y composiciones para tratar el cancer de prostata.
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
CN100528167C (zh) * 2002-10-23 2009-08-19 潘塔希生物科学股份有限公司 用于治疗癌症的包含雌四醇衍生物的药物组合物
EP1583539A2 (en) * 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
NZ597830A (en) * 2006-08-25 2013-02-22 Cougar Biotechnology Inc Methods and compositions for treating cancer comprising abiraterone acetate and prednisone

Also Published As

Publication number Publication date
JP2010501575A (ja) 2010-01-21
CA2661422C (en) 2017-06-27
ES2869343T3 (es) 2021-10-25
JP2024164147A (ja) 2024-11-26
CY1115477T1 (el) 2017-01-04
CN104306977A (zh) 2015-01-28
JP2022185091A (ja) 2022-12-13
PL2061561T3 (pl) 2013-12-31
HUE054495T2 (hu) 2021-09-28
EP2061561B1 (en) 2013-07-10
CN101528308A (zh) 2009-09-09
AU2007287098C1 (en) 2018-03-15
AU2015221447B9 (en) 2017-07-20
DK2061561T3 (da) 2013-10-07
KR20200125776A (ko) 2020-11-04
PT2478907T (pt) 2021-05-26
NO20200775A1 (no) 2009-03-20
NZ597830A (en) 2013-02-22
WO2008024484A1 (en) 2008-02-28
PL2478907T3 (pl) 2021-10-25
JP2015110577A (ja) 2015-06-18
EP2478907A2 (en) 2012-07-25
HRP20130961T1 (hr) 2013-11-22
HK1131577A1 (en) 2010-01-29
JP2012082215A (ja) 2012-04-26
AU2017201764A1 (en) 2017-04-06
EP3804730A1 (en) 2021-04-14
JP6445123B2 (ja) 2018-12-26
AU2018271331A1 (en) 2018-12-20
SI2061561T1 (sl) 2013-11-29
JP2020114851A (ja) 2020-07-30
EP2478907B1 (en) 2021-04-14
EP2478907A3 (en) 2012-08-01
IL257681A (en) 2018-04-30
KR20180003636A (ko) 2018-01-09
JP2021038252A (ja) 2021-03-11
ES2428634T3 (es) 2013-11-08
JP2017052791A (ja) 2017-03-16
KR20150108946A (ko) 2015-09-30
RS62034B1 (sr) 2021-07-30
KR20090059126A (ko) 2009-06-10
AU2015221447A1 (en) 2015-09-17
CA2661422A1 (en) 2008-02-28
NO20091190L (no) 2009-03-20
AU2015221447B2 (en) 2016-12-15
IL197211A0 (en) 2009-12-24
AU2022206696A1 (en) 2022-08-11
JP2018065859A (ja) 2018-04-26
HRP20210670T1 (hr) 2021-06-11
LT2478907T (lt) 2021-06-25
AU2007287098A1 (en) 2008-02-28
RS52956B (sr) 2014-02-28
AU2007287098B2 (en) 2013-08-15
JP2019059750A (ja) 2019-04-18
JP6053279B2 (ja) 2016-12-27
IL227746A0 (en) 2013-09-30
AU2021201649A1 (en) 2021-04-08
JP6740497B2 (ja) 2020-08-12
DK2478907T3 (da) 2021-05-25
SI2478907T1 (sl) 2021-08-31
CY1124221T1 (el) 2022-05-27
EP2061561A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
PT2061561E (pt) Composições para tratar o cancro
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2007144152A3 (en) Extended step-down estrogen regimen
WO2010081032A3 (en) Steroidal compositions
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2010091299A3 (en) Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
NZ609420A (en) Fulvestrant compositions and methods of use
WO2008022349A3 (en) Agents for blood-brain barrier delivery
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
TW200603831A (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
WO2011049948A3 (en) Neuroprotection and myelin repair using nestorone®
WO2008011073A3 (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
WO2009139924A3 (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
MXPA02007117A (es) Composiciones para suministrar un antagonista de cortisol..
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
WO2011022838A8 (en) Polyhydroxylated bile acids for treatment of biliary disorders
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders